Are Analysts Bullish about TG Therapeutics, Inc. (NASDAQ:TGTX) after last week?

May 18, 2018 - By Christine McCrea

Investors sentiment increased to 2 in 2017 Q4. Its up 0.79, from 1.21 in 2017Q3. It is positive, as 12 investors sold TG Therapeutics, Inc. shares while 14 reduced holdings. 17 funds opened positions while 35 raised stakes. 35.20 million shares or 0.20% more from 35.13 million shares in 2017Q3 were reported.
Gam Holding Ag accumulated 98,600 shares. Geode Mngmt Lc holds 0% or 462,270 shares. Stoneridge Ptnrs Ltd Limited Liability Company has 0.09% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 71,998 shares. Royal Bank & Trust Of Canada stated it has 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). Fmr Lc reported 4.95 million shares. Aqr Cap Management Ltd Liability Corporation stated it has 46,537 shares. 3,056 are owned by Victory Mngmt. Trexquant L P holds 0.06% or 67,243 shares in its portfolio. Citadel Advsrs Lc reported 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). Raymond James Associate reported 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Metropolitan Life Insurance Company reported 16,358 shares. State Street invested in 0% or 3.41M shares. 88,271 are owned by D E Shaw And. Zurcher Kantonalbank (Zurich Cantonalbank) has 2,255 shares for 0% of their portfolio. Credit Suisse Ag has 66,893 shares.

Since December 29, 2017, it had 0 buys, and 1 insider sale for $272,051 activity.

TG Therapeutics, Inc. (NASDAQ:TGTX) Ratings Coverage

Among 4 analysts covering TG Therapeutics (NASDAQ:TGTX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 10 analyst reports since November 30, 2017 according to SRatingsIntel. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given on Wednesday, March 21 by H.C. Wainwright. The firm earned “Buy” rating on Thursday, April 19 by Raymond James. FBR Capital maintained TG Therapeutics, Inc. (NASDAQ:TGTX) on Friday, February 2 with “Buy” rating. As per Friday, December 1, the company rating was maintained by B. Riley & Co. The firm has “Buy” rating by FBR Capital given on Wednesday, January 17. H.C. Wainwright maintained TG Therapeutics, Inc. (NASDAQ:TGTX) on Monday, December 11 with “Buy” rating. On Friday, March 9 the stock rating was maintained by FBR Capital with “Buy”. The firm has “Buy” rating given on Monday, December 11 by FBR Capital. Below is a list of TG Therapeutics, Inc. (NASDAQ:TGTX) latest ratings and price target changes.

19/04/2018 Broker: Raymond James Rating: Buy Maintain
21/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $38.0 Initiate
09/03/2018 Broker: FBR Capital Rating: Buy New Target: $27.0 Maintain
02/02/2018 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain
17/01/2018 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain
12/12/2017 Broker: Raymond James Rating: Buy
11/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $33.0 Maintain
11/12/2017 Broker: FBR Capital Rating: Buy New Target: $21.5 Maintain
01/12/2017 Broker: B. Riley & Co Rating: Buy New Target: $21.5 Maintain
30/11/2017 Broker: FBR Capital Rating: Buy New Target: $21.5

The stock increased 0.89% or $0.125 during the last trading session, reaching $14.175. About 275,034 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 23.61% since May 18, 2017 and is uptrending. It has outperformed by 12.06% the S&P500.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $1.10 billion. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

More notable recent TG Therapeutics, Inc. (NASDAQ:TGTX) news were published by: Nasdaq.com which released: “TG Therapeutics, Inc. Announces Upcoming Data Presentations at the 54th Annual Meeting of the American Society of …” on May 17, 2018, also Seekingalpha.com with their article: “TG Therapeutics’ (TGTX) CEO Michael Weiss on Q1 2018 Results – Earnings Call Transcript” published on May 08, 2018, Nasdaq.com published: “Recent Analysis Shows FTD Companies, TG Therapeutics, National HealthCare, Lennox International, PRA Group …” on April 30, 2018. More interesting news about TG Therapeutics, Inc. (NASDAQ:TGTX) were released by: Streetinsider.com and their article: “TG Therapeutics (TGTX) Announces Upcoming Data Presentations at ASCO and EHA” published on May 17, 2018 as well as Nasdaq.com‘s news article titled: “TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2018 Financial Results” with publication date: May 08, 2018.

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: